(l)

Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) A method for the treatment of dry eye and other disorders requiring the wetting of the eye which comprises topically administering to the eye of a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound formula (I)

$$Z^{1}$$

$$Y-A$$

$$N-X$$

$$N-X$$

$$N-X$$

$$R^{2}$$

$$R^{1}$$

$$R^{2}$$

wherein:

 Z^1 , Z^2 independently = H, F, Br, Cl, F, or C_{1-3} alkyl;

 $Y = CH-(CH2)_n$ or CH-O;

n = 0-3:

A = CH or N, provided that when Y = CH-O then A = CH;

 $A^2 = CH \text{ or } N$:

 $X = (CH2)_{0}Y^{2}$ or $(CH2)_{0}Y^{3}(CH2)_{0}Y^{2}$;

 $X^2 = H, OR^5, C_{1-6}$ alkyl, $C(O)OR^6$, or $C(O)N(R^7)H$;

n' = 2-6;

n'' = 2-4:

 $Y^2 = O. S. or NH$

 $Y^3 = O \text{ or } S$;

 $R^1 = H$, or $(C(R^3)(R^4))X^2$; and

 R^2 , R^3 , R^4 , R^5 , R^6 , R^7 independently = H or C_{1-6} alkyl.

2. (original) The method of Claim 1 wherein

 $Z^{1}, Z^{2} = H;$

Y = CH-O;

U.S. Serial No. 10/824,013 Confirmation No.: 5961 Filed: April 14, 2004

```
A = CH:
X = (CH2)_{n} Y^{2};
X^2 = H \text{ or } C(O)OR^6;
n' = 2-4:
Y^2 = O or NH; and
R^2, R^3, R^4, R^6 independently = H or C_{14} alkyl.
```

(original) The method of Claim 2 wherein 3.

 $A^2 = CH$;

 $R^1 = (C(R^3)(R^4))X^2$

R², R⁶ independently = H or C₁₋₄ alkyl; and

R³. R⁴ independently= H or methyl.

- (original) The method of Claim 1 wherein the compound of formula (I) is selected from the group consisting of
- 6-[3-[4-(diphenylmethoxy)piperidino]propylamino][1,2,4]triazolol[1,5,b]-pyridazine;
- 6-[3-[4-(diphenylmethoxy)piperidino]propylamino]-2-methyl[1,2,4]-triazolo[1,5,b]pyridazine;
- 2-[6-[3-[4-(diphenylmethoxy)piperidino]propylamino]imidazo[1,2,b]-pyridazin-2-yl]-2methylpropionic acid;
- 2-[6-[3-[4-(diphenylmethoxy)piperidino]propylamino]imidazo[1,2,b]-pyridazin-2-yl]-2methylpropionic acid dihydrate; and
- 2-[6-[3-[4-(diphenylmethoxy)piperidino]propoxy]imidazo[1,2,b]pyridazin-2-yl]-2-methylpropionic acid.
- (original) The method of Claim 1 wherein the pharmaceutically effective amount of the 5. compound of formula (I) in the composition is 0.001 – 1.0% (w/w).
- (currently amended) The method of Claim 1 wherein the dry eye and other disorders 6. requiring the wetting of the eye is symptoms of dry eye associated with refractive surgery.